Farmaci antidepressivi, intervallo QT e rischio cardiovascolare. Timori fondati?

Translated title of the contribution: Antidepressants, QT interval and cardiovascular risk. Justified concerns?

Peter J. Schwartz, A. C. Altamura

Research output: Contribution to journalArticlepeer-review


Over the last 20 years there were multiple initiatives of Regulatory Agencies, both in the U.S. (FDA) and in Europe (EMA), which created disconcert and alarm in the world of psychiatry. Most often these initiatives have involved interactions, considered potentially dangerous, between antipsychotics or antidepressants and cardiovascular risks. The latest were related to two drugs known to be effective antidepressants such as citalopram (by FDA) and its active enantiomer, escitalopram (only by the EMA), in connection with a possible lengthening of the QT interval. This critical review, which provides the joint opinion of a cardiologist and a psychiatrist both with specific expertise, aims to put into perspective the actions of regulatory agencies regarding the association between antidepressants, QT interval and cardiac arrhythmias; to review the physiological basis and mechanisms underlying this issue; to critically analyze the relevant evidences and the other cardiovascular effects of these drugs, and to draw reasonable conclusions for psychiatrists who treat depressed patients.

Translated title of the contributionAntidepressants, QT interval and cardiovascular risk. Justified concerns?
Original languageItalian
Pages (from-to)183-191
Number of pages9
JournalItalian Journal of Psychopathology
Issue number2
Publication statusPublished - Jun 2012

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology


Dive into the research topics of 'Antidepressants, QT interval and cardiovascular risk. Justified concerns?'. Together they form a unique fingerprint.

Cite this